切莱利思林可以保护抗乙氨基诱导的急性肝损伤:从肠道微生物群和多奥米克分析的见解
Jinlong Liu1, Yanfei Zhang1, Hao Wu1
1School of Pharmaceutical Sciences, Jilin Medical University, No.5, Jilin Street, Fengman District, Jilin 132013, China.
Antioxidants (Basel, Switzerland)
|September 27, 2025
概括
切莱里思林 (CHE) 通过减少炎症和氧化应激,保护免受乙氨基诱导的急性肝损伤 (ALI). CHE还恢复了肠道微生物群的平衡,突出了其作为天然肝脏保护剂的潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 毒理学 毒理学 毒理学
- 微生物学 微生物学
背景情况:
- 切利氨酸 (CHE) 来自*Chelidonium majus* L.,具有抗氧化和抗炎性质.
- CHE对急性肝损伤 (ALI) 的保护机制尚未完全理解.
研究的目的:
- 在小鼠中研究CHE对乙氨基 (APAP) 诱导的ALI的保护作用.
- 阐明潜在的机制,包括肠道微生物群的调节,氧化应激和炎症.
主要方法:
- 小鼠接受了CHE (15和30毫克/公斤) 治疗,随后给予APAP.
- 分析包括肝功能测试 (ALT,AST),炎症标志物 (IL-6,IL-1β,TNF-α),氧化应激标志物 (MDA,H2O2,CAT,SOD,GSH),肠道微生物群概况 (16S rRNA测序) 和代谢学.
主要成果:
- CHE显著降低了ALT和AST水平,表明肝脏保护.
- CHE缓解了APAP诱导的炎症性细胞因子和氧化应激标志物的增加.
- CHE治疗改变了肠道微生物群的组成,显著增加了*Barnesiella intestinihominis*的丰度.
- CHE逆转了代谢干扰,并抑制了关键的氧化和炎症信号通路.
结论:
- 切莱里思林显示出对APAP诱导的ALI具有显著的肝保护作用.
- 通过减少氧化应激,抑制炎症和调节肠道微生物群组成,CHE发挥了保护作用.
- CHE代表了一种有前途的天然治疗剂,用于治疗急性肝损伤.
相关概念视频
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
185
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
185
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
215
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
215
01:16Hepatic Drug Excretion: Influencing Factors
526
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
526
01:22Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
826
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
826
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
214
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
214